Orexo AB - Financial calendar 2008

Orexo AB - Financial calendar 2008

Orexo AB (publ) today announced the following preliminary dates for the release
of its quarterly reports and the Annual General Meeting in 2008:

Q4 2007, Full Year Report 2007 - February 15, 2008
Q1 2008, Interim Report January - March 2008 - May 7, 2008
Q2 2008, Interim Report January - June 2008 - August 14, 2008
Q3 2008, Interim Report January - September 2008 - November 10, 2008

Annual General Meeting (Stockholm) - April 3 at 17.00.


For more information, please contact 
Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18 780 88 44, e-mail: claes.wenthzel@orexo.com





TO THE EDITORS
About Orexo

Orexo is a specialty pharmaceutical company, focusing on development of new,
patented drugs by combining well-documented substances with innovative
technologies, and the development of new treatments for respiratory and
inflammatory diseases.

Orexo has a broad and competitive late-stage product portfolio, including two
marketed products, five products in clinical phase and two undergoing
registration. 

To date, Orexo have out-licensed the market rights for Rapinyl for the US, the
EU and Japan markets, and signed a research collaboration with Boehringer
Ingelheim regarding the development of a new class of drugs to treat pain and
inflammation. Also, Orexo has established a Nordic sales force by entering into
a joint venture with ProStrakan.

Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange
Stockholm, Small Cap (ticker: ORX).  

www.orexo.com